incidence in subjects treated with the different ChEIs. Conclusions: Subjects with mild to moderate AD treated in routine clinical practice with donepezil were more adherent to pharmacotherapy, and had a lower risk of GI AEs compared with rivastigmine or galantamine. This finding accords with results reported in the randomised clinical trial literature.
tributory factor in up to 13% of all deaths [4] . In England alone, the estimated annual economic burden of late-onset dementia is estimated to be GBP 14.3 billion [5] .
At present, there are 2 classes of medication approved for the treatment of AD. The cholinesterase inhibitors (ChEIs) are indicated for the treatment of mild to moderate AD only, and include donepezil (Aricept ), galantamine (Reminyl ) and rivastigmine (Exelon ) [6] . The N-methyl-D -aspartate antagonist memantine (Ebixa ) is the only treatment licensed for the treatment of moderate to severe dementia. The National Institute for Health and Clinical Excellence does not recommend memantine for people with moderately severe to severe AD in England and Wales unless it is used as part of a clinical trial (research) [6] , and in Scotland it is not recommended for use in this population [7] .
Results from randomised clinical trials (RCTs) have indicated that treatment with ChEIs stabilises or slows decline in cognition, function, behaviour and global change in subjects with AD [2, [8] [9] [10] . However, the majority of RCTs examining the efficacy and safety of the ChEIs have been placebo-controlled studies and, to ensure the internal validity of their findings, many RCTs exclude subjects with multiple comorbid conditions [11] . Consequently, subjects enrolled in RCTs may not be representative of AD patients treated in a 'real-world' setting, limiting the external validity of study results [12] . In contrast, studies performed in a naturalistic setting may include a broader range of patients more akin to those seen in clinical practice and are particularly useful for collecting real-life descriptive data on the efficacy and safety of pharmacological treatments for chronic diseases such as AD [13, 14] .
The majority of RCTs and systematic reviews conducted to date have reported no significant differences between the ChEIs in terms of effects on cognition [8, [15] [16] [17] [18] . However, across trials, differences have been reported in the incidence of AEs (generally lowest for donepezil and highest for rivastigmine) [8, 19, 20] . Consequently, the present systematic review was conducted to review whether the difference in the incidence of AEs between ChEIs reported in the RCT literature was also reflected in the 'real-world' healthcare setting.
Methods
Electronic databases and conference proceedings were searched to identify relevant studies. Medline, EMBASE and the Cochrane Library were accessed on October 10, 2008 . There were no restrictions by date of publication. The search combined both MeSH and free-text terms for 'dementia' or 'Alzheimer's disease' with the interventions 'donepezil', 'rivastigmine' and 'galantamine' and publication type 'cohort', 'retrospective' or 'naturalistic' study. The focus of the database search was on head-to-head studies of donepezil compared with rivastigmine and/or galantamine only. Non-comparative observational study designs were excluded from consideration ( table 1 ) .
The following conference proceedings were hand-searched (2003-2008 inclusive): International Conference on Alzheimer's Disease, European Federation of Neurological Societies Congress, and European College of Neuropsychopharmacology Congress. Cited references from included studies and previously published reviews were also searched.
Identified studies were independently assessed by 2 reviewers in order to ascertain whether they met a set of pre-defined inclusion/exclusion criteria ( table 1 ) , and discrepancies were resolved by a third party. The primary outcome measures of the review were the incidence of overall AEs, withdrawals due to AEs and the incidence of individual AEs where reported. The mean daily dose of ChEI and number of subjects tolerating a particular dose were also recorded.
Due to potential heterogeneity in included studies (e.g. differences in study design, study duration, titration schedule, definition of individual AEs), it was decided a priori to conduct a qualitative analysis of the results rather than perform a meta-analysis via a direct or indirect comparison.
Data were extracted from eligible publications by a reviewer into an Excel spreadsheet. A second reviewer checked the resulting extraction and any discrepancies were resolved through discussion.
Quality Assessment
It is necessary to critically examine the methodological design of head-to-head studies in order to assess the credibility and interpretation of results. Two reviewers independently assessed the methodological quality of the included observational studies using the Newcastle-Ottawa Scale (NOS) [21] . This scale is specifically designed to appraise the methodological quality of comparative cohort and case control studies. It has been partly validated, and is the scale recommended by the Cochrane Non-Randomised Studies Method Working Group [22] . The 8-item instrument consists of 3 subscales: selection of subjects (4 items), comparability of subjects (1 item) and assessment of outcome/exposure (3 items). Studies were awarded 1 point for each item they met, with a maximum of 2 points awarded for comparability of subjects. Overall study quality was defined as poor (score of 0-4), moderate (5) (6) or good (7) (8) (9) .
Results
In total, 2,599 citations were identified through electronic database searching, of which 2,498 were excluded on the basis of title and abstract ( fig. 1 ). On re-application of the review inclusion criteria to the 101 full-text papers, a further 91 were excluded. Two additional full-text studies were identified via hand-searching. Therefore, 12 studies met the inclusion criteria, and were included in the systematic review [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] .
Of the 12 relevant studies undergoing assessment for methodological quality, 1 was assessed to be of poor quality (score of 4 out of 9 on the NOS) [34] and 2 were found to be of moderate quality (range 5-6 out of 9 on the NOS) [24, 25] . The study by Hughes et al. [25] compared nursing home residents who may be more likely to have advanced AD than subjects in the general population. One study [34] was only available as an abstract and therefore reported limited study details, which resulted in a score of 4 on the NOS scale. The remaining 9 studies [23, [26] [27] [28] [29] [30] [31] [32] [33] were judged to be of good quality (range: 7-9).
Study characteristics are detailed in table 2 . Eleven studies were published in full [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , and 1 was available as a conference abstract [34] . Three foreign-language publications with English abstracts were translated in order to extract relevant results [23, [29] [30] [31] .
Six of the studies were retrospective analyses of patient medical records [23, 24, 30, 33] or prescription databases [25, 29] , and the remaining 6 were prospective open-label cohort studies [26-28, 31, 32, 34] .
For both retrospective and prospective studies, donepezil was the most frequently prescribed ChEI, followed by rivastigmine and galantamine ( table 2 ) . Donepezil versus rivastigmine versus galantamine:
• retrospective analyses n = 6,294 vs. 1,842 vs. 809, respectively; • prospective studies n = 4,034 vs. 2,143 vs. 418, respectively. Two of the included studies compared donepezil and rivastigmine only [23, 24] , while the remaining 10 reported a head-to-head comparison of all 3 ChEIs [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] .
Retrospective Study Characteristics
Four of the six retrospective studies were based on examination of medical records from subjects with mild to moderate AD enrolled in specialist dementia/psychiatric units [23, 24, 33] or geriatric centres [30] ( table 2 ) . Treatment follow-up ranged from at least 6 months [23, 24] to up to 3 years [33] . Hughes et al. [25] reported the incidence of gastrointestinal (GI) AEs obtained from a healthstatus questionnaire completed by nursing home residents treated with a ChEI for up to 1 year. The final study assessed the notification of AEs (all cause and treatment related) in ChEI-treated subjects reported to 4 pharmacovigilance centres in France [29] .
Prospective Study Characteristics
Four of the six prospective studies reported data from the CRONOS project, a national project initiated by the Italian government in October 2000 [26, 27, 31, 32] . The project involved 503 Alzheimer evaluation units (AEUs) and aimed to standardise ChEI prescriptions and to assess their effects on defined outcomes (cognition, functional status, behaviour) in non-selected subjects with mild to moderate AD [35] . No restrictions on which ChEI was prescribed were applied in 3 of the 4 studies [26, 27, 31, 32] , although galantamine only became available for treatment from April 2001 onwards. However, in the study by Aguglia et al. [31] , treatment was assigned in a pseudo-randomised fashion based on arrival at the AEU following the availability of galantamine.
The study cohort investigated by Raschetti et al. [32] consisted of 5,462 treatment-naïve subjects treated at 118 of the 503 AEUs between September 2000 and December 2001. Subjects were followed until discontinuation for any reason, admission to hospital or nursing home, cognitive decline (MMSE ! 10) or death; 2,853 subjects completed 9 months of therapy. Mossello et al. [26] reported safety data for 407 subjects referred to 2 AEUs between September 2000 and July 2002. However, only 5% of subjects (n = 19) were prescribed galantamine in this study. In the third study, results from 354 subjects evaluated at a single AEU between November 2000 and November 2002 were reported [27] . In the final study, 242 treatmentnaïve subjects referred to a single AEU were followed for 6 months [31] .
The remaining 2 studies evaluated subjects with probable AD referred to primary health care centres who underwent ChEI treatment for 6 [28] or 9 months [34] . Previous treatment with a ChEI was not permitted in 1 study [34] , and not reported as an exclusion criterion in the other [28] .
Details of the main safety/tolerability data reported in the studies are given in tables 3-7 .
Frequency of Total AEs
The incidence of total AEs was reported in 3 retrospective studies, 2 comparing donepezil with rivastigmine [23, 24] and 1 comparing all 3 ChEIs [33] . A similar incidence of AEs was reported between donepezil and rivastigmine (donepezil 43.9%, range 19.5-71.3% vs. rivastigmine 48.1%, range 20.1-78%; table 5 ) [23, 24, 33] . In the single study reporting a head-to-head comparison between the 3 ChEIs, the highest incidence of all AEs was reported in galantamine-treated subjects (5/9, 55%) compared with 46.1% in rivastigmine-(12/26) and 40.8% in donepezil-treated subjects (51/125) [33] . Although the study by De La Gastine et al. [29] reported the incidence of all observed AEs, the data were of limited use as the 1 A nursing-home resident questionnaire used to collect information on the health status of residents. It includes information on health conditions, physical functioning, mood and behavioural patterns, oral/nutritional status, and special treatments and procedures. 2 Mean study period (time frame between treatment initiation and the last Minimum Data Set assessment). 3 Study examined subjects referred to specialist cognitive deficit unit (Unit of Evaluation for Alzheimer; UVA). Until galantamine became available, the treatment (donepezil or rivastigmine) was chosen by the clinician. Subsequently it was assigned pseudo-randomly based on subjects' order of arrival at the UVA, in the sequence: donepezil, rivastigmine, galantamine. 4 Study examined subjects referred to specialist cognitive deficit unit (UVA). 5 66/354 subjects met the inclusion criteria and were enrolled. 6 Historical control group: subjects diagnosed with AD between 1991 and 1996 that had not received treatment with ChEIs and had neuropsychological assessments with MMSE at 6 months.
numbers of subjects treated with each ChEI were not reported. Therefore, it was not possible to calculate the proportion of AEs observed for the individual ChEIs. However, the proportion of reported AEs that were thought to be treatment related could be imputed: 12/41 (29.3%) for donepezil, 5/16 (31.3%) for rivastigmine and 4/8 (50%) for galantamine.
A single prospective cohort study enrolling approximately 5,000 subjects [32] with probable mild to moderate AD reported the incidence of total AEs, which was reported to be significantly higher (p ! 0.001) in rivastigmine-(306/1,278, 23.9%) or galantamine-treated subjects (52/163, 31.9%) compared with donepezil (425/2,809, 15.1%). This difference was primarily a result of a higher incidence of GI AEs [donepezil (6%) vs. rivastigmine (14%) vs. galantamine (24%)].
Withdrawals due to AEs
Three retrospective studies reported the incidence of withdrawals due to AEs [24, 30, 33] ( tables 3 , 4 ). While 1 study [24] reported a numerically lower non-significant withdrawal rate due to AEs between donepezil (14.6%) and rivastigmine (22.8%), a second study [33] found a statistically significant higher proportion of withdrawals due to nausea in rivastigmine compared with donepeziltreated subjects ( table 3 : 15.4 vs. 3.2%, respectively; p = 0.03). A third study reported numerically more withdrawals in donepezil compared with galantamine-treated subjects (10 vs. 2%), but the difference was not statistically significant (p = 0.06) [30] . This study only included 5 rivastigmine-treated subjects, limiting the usefulness of any comparison with the other ChEIs ( table 4 ) .
Relevant data were reported in 2 prospective studies [26, 28] : one 6-month study reported a numerically lower incidence of AE-related withdrawals in donepezil-treated subjects (2.5%) compared with rivastigmine (3.3%) and galantamine-treated subjects (6.3%) [28] , while a second 9-month study reported a significantly lower number of withdrawals following treatment with donepezil (3%) compared with both rivastigmine (17%) and galantamine (21%, p ! 0.01) [26] . The latter difference resulted from a higher incidence of withdrawals due to GI AEs, which occurred in 1.2% of donepezil-, 11.4% of rivastigmine-, and 15.8% of galantamine-treated subjects ( table 3 ) .
A head-to-head comparison of the incidence of total or individual GI AEs (nausea, vomiting, diarrhoea) was reported in 8 studies ( table 5 ) [23-25, 27, 31-34] .
Gastrointestinal AEs
The incidence of total GI AEs were reported in 2 retrospective studies [23, 24] , while 3 studies reported the incidence of individual GI AEs (nausea, vomiting, diarrhoea, abdominal cramps) [24, 25, 33] . Considering total GI AEs, these were reported more frequently in rivastigmine-compared with donepezil-treated subjects ( [23, 24] . The difference reached statistical significance (p = 0.013) in 1 study, rivastigmine-treated subjects over 4 times more likely to experience a GI AE compared with donepezil-treated subjects (RR 4.39, 95% CI 1.38-13.92) [23] . The level of nausea in galantamine-treated subjects was reported to be similar to donepezil ( ϳ 11%) and lower compared to rivastigmine (20.7-23.1%) [24, 33] . However, following treatment with galantamine, subjects were significantly more likely (p = 0.035) to report diarrhoea (8.9%) compared with both donepezil (6.4%) and rivastigmine (6.8%) [25] . No differences between ChEIs were reported for vomiting [24, 25] , constipation [24] or abdominal cramps [25] ( table 5 ) .
Two prospective studies reported the incidence of total GI AEs [31, 32] , while the incidence of individual GI AEs was reported in 3 studies [27, 31, 34] ( table 5 ) . Total GI AEs were reported at a similar incidence across the 3 treatment groups in 1 study [31] , but occurred in more galantamine-(24%) and rivastigmine-treated subjects (14%) compared with donepezil in a second study (6%) [32] . Considering individual GI AEs ( table 5 ), the report- ed incidences of nausea and vomiting were comparable between ChEIs in 1 study [31] , but numerically higher in rivastigmine-(nausea 14% and vomiting 10%) and galantamine-treated subjects (12 and 8%, respectively) compared with donepezil (7 and 6%, respectively) in a second study [27] . Both studies reported a numerically higher incidence of diarrhoea in rivastigmine-(2.4-10%) and galantamine-treated subjects (5.8-8%) compared with donepezil (0-5%) [27, 31] . The study by Shua-Haim et al. [34] enrolled only a small number of subjects (n = 29), and nausea was reported in a single rivastigmine-treated subject. The incidence of abdominal pain was reported in a single study, and was higher in rivastigmine and galantamine-treated subjects (9 and 7%, respectively) compared with donepezil-treated subjects (4%) [27] .
Other AEs
Although the incidences of cardiovascular and CNSrelated AEs were reported in 5 prospective studies, these AEs occurred in a minority of subjects and there were very few statistically significant differences reported between the 3 ChEIs ( tables 6 , 7 ) [23-25, 29, 33] . One study reported that galantamine-treated subjects were significantly (15.6%; p ! 0.01) less likely to lose weight compared with either rivastigmine-(20.0%) or donepezil-treated (20.3%) subjects [25] .
Cardiovascular and CNS-related AEs were reported in 3 retrospective studies [27, 31, 34] . As for the prospective studies, both cardiovascular and CNS-related AEs were reported in a low number of subjects, and there were no statistically significant differences reported between the ChEIs ( tables 6 , 7 ).
Maximum Tolerated Dose Proportions
Two retrospective studies reported the number of subjects reaching a maximum tolerated dose [23, 24] . Fewer rivastigmine-treated subjects (4.9-21%) received a daily dose of 12 mg/day compared with donepezil-treated subjects who tolerated a dose of 10 mg/day (47-60%), with the difference reaching statistical significance (p ! 0.001) in 1 study [24] .
A single prospective study reported relevant data [28] . At 6 months, 82.5% of donepezil subjects were treated with 5 mg/day, compared with 83.4% of rivastigminetreated subjects receiving 6 6 mg/day and 65.7% of galantamine subjects treated with 6 16 mg/day. Severe AE, requiring hospitalization. 2 Neuropsychiatric disorders (headache, sleepiness, insomnia, agitation and irritability; n = 2), GI AEs (n = 3), and neuropsychiatric and GI AEs (n = 3). 3 Non-significant difference between treatment groups. Reported as adverse drug reaction. Incidence of non-CNS-related AEs reported in retrospective and prospective observational ChEIs studies Non-significant difference between treatment groups. 3 Headache, sleepiness, insomnia, agitation and irritability. NR = Not reported. * p < 0.001 in favour of donepezil. 1 Percentage of patients who did not tolerate a minimum effective dose: 5 mg for donepezil and 6 mg for rivastigmine. 2 Both treatments initiated at lowest marketed dose (5 mg/day for donepezil and 3 mg/day for rivastigmine) and subjects were seen after 1 month. Dose titration was slow with minimal intervals of 1 month. In case of AEs, subjects were re-titrated to a maximum previously well-tolerated dose and no further dose escalation was undertaken. 3 Patients were commenced on the smallest dose recommended and followed up after 4 weeks. If the drug was tolerated, dose was increased and an efficacy assessment carried out in 3-4 months, at which time an assessment was made whether to continue treatment, after consulting with patient, carers and considering cognitive test scores. 4 Dose at 1-year follow up. 5 Nonsignificant difference between treatments: defined as 5/10 mg donepezil and 9-12 mg rivastigmine. 6 Information only available for the overall period that a resident was on therapy. Dosage shown is the median daily dose for residents whose therapy ended during days 43-365. 7 Donepezil initiated at 5 mg/day and neurologist increased dose to 10 mg/day in the following control visit (between 4 and 8 months) if subject tol erated the treatment with 5 mg/day. 8 Rivastigmine initiated at 3 mg/day during the first month. Caregivers instructed to progressively increase it to 6 and 9 mg/day during the following 2 months. 9 Galantamine initiated at 8 mg/day during the first month. Caregivers instructed to progressively increase it to 16 and 24 mg/day during the following 2 months.
10 Donepezil (5 mg/day for 4 weeks) followed by a maintenance dose (10 mg); 11 Rivastigmine 1.5 mg b.i.d. 12 Galantamine 4 mg b.i.d. for 4 weeks followed by 8 mg b.i.d. as a maintenance dose. 13 5 mg for donepezil and 3-6 mg for rivastigmine.
14 10 mg for donepezil and 9-12 mg for rivastigmine.
Discussion
The aim of the present systematic review was to assess qualitatively the safety and tolerability of the ChEIs for the treatment of AD in a real-world setting using headto-head studies comparing ChEIs as the evidence base. The tolerability of a treatment is particularly important for a condition such as AD, where patients being treated tend to be elderly and have significant medical co-morbidity and polypharmacy. Consequently, any treatmentrelated AEs can be clinically significant, and may result in treatment discontinuation.
Possible limitations of the dataset in the present review should be highlighted and include heterogeneity in study design ( table 2 ) , a small number of patients in some treatment arms [30, 34] , limited data on the relationship between dosing regimen and the incidence of GI AEs [25] and the short treatment duration of some studies (e.g. 6 months in 2 of the prospective studies) [28, 31] . It has been suggested that clinically relevant differences in a chronic condition such as AD can only be demonstrated after relatively long treatment durations [36] . However, shorterterm studies are valid for evaluating the benefits of treatments and report valuable information with regard to initial efficacy, tolerability and compliance. With regard to study design, between-study heterogeneity in 'real-world' studies is more likely to be encountered compared with RCTs, which have more standardised study design requirements. In the present review, studies were grouped on the basis of prospective or retrospective design. Heterogeneity is more apparent in the retrospective studies which differ more with regard to included subjects and healthcare setting compared with the prospective studies. However, despite this variability, a pattern of fewer total and GI AEs was still discernible in donepezil-treated subjects compared with rivastigmine and galantamine treatment in both prospective and retrospective studies.
The present review also has several strengths. The use of a comprehensive search strategy (electronic databases in addition to selected conference proceedings) maximised the likelihood of identifying all potentially relevant publications. Duplicate quality assessment of included studies reduced the potential for bias in this component of the review. Results were reported from studies reflecting the real-world conditions of care, ChEI dosing regimens and disease co-morbidity, which cannot be obtained from RCT-protocol-based studies. Therefore, subjects enrolled in the 'real-world' studies in the present review may be considered to be more representative of the general population of AD subjects treated in everyday clinical practice compared with participants in RCTs.
Indeed, the external validity and generalisability of many RCTs have been questioned [12] as a consequence of the fact that they may include highly selected study populations due to the enrolment of subjects meeting strict inclusion criteria. For example, several of the AD RCTs performed to date have excluded subjects with comorbidities (e.g. diabetes, asthma or COPD) [37] [38] [39] or those taking concomitant medications (e.g. antidepressants, sedatives or antihypertensive agents) [40, 41] . In addition, several of the RCTs have employed an enforced titration schedule which dictates that dosages be escalated to certain levels at specified time intervals leading to a more rapid escalation than that recommended in the approved product labelling [39] [40] [41] [42] [43] [44] . The recommended dose escalation schedules for the individual ChEIs are [45] :
• Donepezil: subjects initiated at 5 mg/day for at least 1 month prior to an increase to 10 mg/day. • Rivastigmine: subjects initiated at 1.5 mg twice daily. At 14-day intervals the dose may be increased by increments of 1.5 mg twice daily up to a maximum dosage of 6 mg twice daily.
• Galantamine: subjects initiated at 4 mg twice daily for 4 weeks, after which time the dose can be increased to 8 mg twice daily for at least a further 4 weeks. A further increase to a final maintenance dose of 12 mg twice daily may be permitted. Three of the six prospective studies included in the present review provided details of the dose titration regimen used [27, 28, 34] . The titration schedules used were not homogeneous between the ChEIs. For example, in the study by Lopez-Pousa et al. [28] the caregivers of subjects treated with rivastigmine or galantamine were instructed to progressively increase the treatment dose over a 2-month period until the maximum tolerated dose was reached, compared with many donepezil-treated subjects who began on 5 mg/day but did not have their treatment titrated up to 10 mg/day by their neurologist until after the 6-month follow-up appointment.
One of the aims of the present review was to compare the incidence of AEs obtained in the real-world setting with those from the RCT setting. While the results are not directly comparable with those from RCTs due to the absence of an untreated cohort arm, results can be compared with data from the treatment arms of the RCTs. A number of previous systematic reviews have examined the efficacy and tolerability of ChEIs in the treatment of AD [8, 20, 46, 47] . These reviews have focused on data from RCTs only, with between 6 [47] and 43 RCTs [46] meeting the inclusion criteria of the various reviews. However, the majority of RCTs performed to date have been placebo controlled and there is a paucity of headto-head comparisons, with only 6 such RCTs included in these systematic reviews [15-17, 38, 48, 49] . The most frequently reported AEs in RCTs were GI in nature (nausea, vomiting, diarrhoea) [8] , and this was confirmed in the present study. In the head-to-head RCTs, rates of treatment-emergent GI AEs were generally higher in the galantamine group compared with donepezil, and generally higher in the rivastigmine group compared with donepezil [20, 25] . For example, the mean frequency for nausea was 11% for donepezil, 44% for rivastigmine and 24% for galantamine [25] . This finding is consistent with the current results from studies in a routine clinical setting ( table 5 ) [23-25, 27, 31, 32] .
The incidence of GI AEs reported in the present review was lower than that observed from the RCT data ( table 5 ) [8, 20, 46, 47] . For example, whereas the incidence of nausea was reported to be 44% in rivastigminetreated subjects within RCTs [8] , the highest reported incidence was 23.1% in a routine clinical setting [33] . This difference may result from a stricter monitoring of subjects enrolled in RCTs, a possible underreporting of AEs in the everyday clinical setting, or the higher titration speed adopted in the RCT setting. Research has shown that the incidence of AEs is directly related to the dose of ChEI administered [32, 50] , with enforced titration schedules (e.g. escalation to 10 mg/day donepezil after only 1 week at 5 mg/day) increasing the likelihood of experiencing AEs [39] . Therefore, a slow and gradual increase in the dose of ChEI in the everyday clinical setting is an important factor for obtaining a balance between clinical efficacy and tolerability, thereby maximising any positive effects on cognitive function while minimising the incidence of AEs [23] .
Non-GI AEs were reported by a small number of subjects in the majority of studies in the present review ( tables 6 , 7 ) and, in contrast to GI AEs, the incidence of such events were comparable with that observed in previous systematic reviews of RCTs [8, 46, 51] . One exception was weight loss which was reported in 15-20% of ChEI-treated subjects in a single retrospective study [25] compared with 7-11% in the RCT setting [8] . This may be attributed to differences in the study populations: the retrospective study examined nursing home residents who are more likely to have advanced AD and co-morbid conditions associated with an increased susceptibility to weight loss compared with subjects enrolled in RCTs. A previous systematic review of the RCT literature reported that between 3 and 7% of donepezil-treated subjects (5-10 mg/ day) experienced insomnia [51] . The incidence of insomnia was not reported for rivastigmine-or galantaminetreated subjects. However, in the present review the incidence of insomnia was similar for all the ChEIs (5-7%;  table 7 ) , and within the range reported from the RCT evidence [51] .
Two studies reported that a significant number of subjects were treated with less than the minimal effective dose of ChEI ( table 8 ) [25, 32] . For example, in the study by Hughes et al. [25] , data on drug dosage for all 3 ChEIs indicated that approximately 50% of subjects were being treated with less than the clinically effective dose at 43 days after treatment initiation. Indeed, the daily treatment doses of ChEIs reported in the present analysis ( table 8 ) were lower than those reported in the RCT literature [46] . Again, this may be a consequence of the more relaxed exclusion criteria in the present studies, leading to the inclusion of subjects with co-morbidities who are less able to tolerate higher treatment doses.
Conclusion
The body of evidence from studies conducted in an everyday clinical setting suggests that donepezil has a more advantageous tolerability profile compared with rivastigmine and galantamine, exemplified by fewer withdrawals due to AEs, a lower incidence of GI AEs, and more subjects achieving a maximum tolerated dose. The findings from the present review are clinically relevant, and are applicable to the day-to-day treatment of subjects with AD. Further well-designed head-to-head studies comparing the ChEIs are necessary to confirm these findings.
